Israel’s Redhill Biopharma announced preliminary positive data from a pre-clinical study with RHB-104 for the treatment of Type 1 diabetes. Trials of RHB-104 for treating Crohn’s disease and Multiple Sclerosis are on going and are planned for Rheumatoid Arthritis.
http://online.wsj.com/article/PR-CO-20140626-905884.html